Literature DB >> 8219111

Enhancing effects of IL-2 on M-CSF production by human peripheral blood monocytes.

M Misago1, J Tsukada, R Ogawa, M Kikuchi, T Hanamura, S Chiba, S Oda, I Morimoto, S Eto.   

Abstract

Monocytes have the capacity to produce granulopoietic factors such as M-CSF and G-CSF. Our findings here showed that interleukin-2 (IL-2), at a concentration of more than 0.05 ng/ml, led to a 12-fold increase in the production of M-CSF in the human peripheral blood mononuclear cells after 72 h incubation compared to the control culture. Even in purified monocyte cultures with added IL-2, a 3-fold increase in M-CSF production was observed at an IL-2 concentration of 50 ng/ml. The enhancing effect of IL-2 on M-CSF secretion was also observed when IL-2-stimulated non-phagocytic cell-conditioned medium was added to monocyte cultures. These results indicated that IL-2, both directly and indirectly, activated monocytes to enhance the production of M-CSF. In addition, the expression of IL-2 receptor (CD25) on monocytes was more enhanced in cultures containing IL-2 than in cultures without IL-2. On the other hand, IL-2 did not induce G-CSF production in purified monocytes. These in vitro results suggest that when IL-2 is used clinically, the various biological activities of M-CSF should also be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219111

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  2 in total

1.  Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent.

Authors:  C Söderberg-Nauclér; D N Streblow; K N Fish; J Allan-Yorke; P P Smith; J A Nelson
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo.

Authors:  Jennifer M Curry; Tim D Eubank; Ryan D Roberts; Yijie Wang; Nabendu Pore; Amit Maity; Clay B Marsh
Journal:  PLoS One       Date:  2008-10-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.